Cellectis (ALCLS) - Net Assets
Based on the latest financial reports, Cellectis (ALCLS) has net assets worth €100.48 Million EUR (≈ $117.47 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€343.05 Million ≈ $401.06 Million USD) and total liabilities (€242.57 Million ≈ $283.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cellectis liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €100.48 Million |
| % of Total Assets | 29.29% |
| Annual Growth Rate | 13.07% |
| 5-Year Change | -57.57% |
| 10-Year Change | -54.54% |
| Growth Volatility | 247.53 |
Cellectis - Net Assets Trend (2002–2024)
This chart illustrates how Cellectis's net assets have evolved over time, based on quarterly financial data. Also explore Cellectis assets under control for the complete picture of this company's asset base.
Annual Net Assets for Cellectis (2002–2024)
The table below shows the annual net assets of Cellectis from 2002 to 2024. For live valuation and market cap data, see ALCLS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €131.03 Million ≈ $153.19 Million |
+54.71% |
| 2023-12-31 | €84.69 Million ≈ $99.02 Million |
-32.75% |
| 2022-12-31 | €125.94 Million ≈ $147.24 Million |
-46.74% |
| 2021-12-31 | €236.47 Million ≈ $276.46 Million |
-23.43% |
| 2020-12-31 | €308.85 Million ≈ $361.07 Million |
-13.12% |
| 2019-12-31 | €355.47 Million ≈ $415.58 Million |
-21.05% |
| 2018-12-31 | €450.27 Million ≈ $526.41 Million |
+57.49% |
| 2017-12-31 | €285.90 Million ≈ $334.25 Million |
+4.33% |
| 2016-12-31 | €274.05 Million ≈ $320.39 Million |
-4.92% |
| 2015-12-31 | €288.22 Million ≈ $336.95 Million |
+298.17% |
| 2014-12-31 | €72.39 Million ≈ $84.63 Million |
+988.46% |
| 2013-12-31 | €6.65 Million ≈ $7.77 Million |
-91.86% |
| 2012-12-31 | €81.69 Million ≈ $95.50 Million |
+120.64% |
| 2011-12-31 | €37.02 Million ≈ $43.28 Million |
-26.15% |
| 2010-12-31 | €50.13 Million ≈ $58.60 Million |
-31.54% |
| 2009-12-31 | €73.22 Million ≈ $85.60 Million |
+58.45% |
| 2008-12-31 | €46.21 Million ≈ $54.03 Million |
+6.13% |
| 2007-12-31 | €43.54 Million ≈ $50.91 Million |
+630.59% |
| 2006-12-31 | €5.96 Million ≈ $6.97 Million |
-34.56% |
| 2005-12-31 | €9.11 Million ≈ $10.65 Million |
+126.00% |
| 2004-12-31 | €4.03 Million ≈ $4.71 Million |
-37.01% |
| 2003-12-31 | €6.40 Million ≈ $7.48 Million |
-27.20% |
| 2002-12-31 | €8.79 Million ≈ $10.27 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cellectis's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 32960700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €5.89 Million | 4.49% |
| Other Comprehensive Income | €-39.54 Million | -30.17% |
| Other Components | €494.29 Million | 377.22% |
| Total Equity | €131.03 Million | 100.00% |
Cellectis Competitors by Market Cap
The table below lists competitors of Cellectis ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
I-Sheng Electric Wire & Cable Co Ltd
TW:6115
|
$282.32 Million |
|
Protara Therapeutics Inc
NASDAQ:TARA
|
$282.32 Million |
|
West Wits Mining Ltd
AU:WWI
|
$282.52 Million |
|
Omega Flex Inc
NASDAQ:OFLX
|
$282.54 Million |
|
FVCBankcorp Inc
NASDAQ:FVCB
|
$282.15 Million |
|
Idun Industrier AB Series B
ST:IDUN-B
|
$282.11 Million |
|
Sonda S.A
SN:SONDA
|
$282.02 Million |
|
Oak Valley Bancorp
NASDAQ:OVLY
|
$282.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cellectis's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 84,695,000 to 131,033,000, a change of 46,338,000 (54.7%).
- Net loss of 36,761,000 reduced equity.
- Share repurchases of 82,822,000 reduced equity.
- New share issuances of 82,822,000 increased equity.
- Other comprehensive income decreased equity by 2,847,000.
- Other factors increased equity by 85,946,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-36.76 Million | -28.05% |
| Share Repurchases | €82.82 Million | -63.21% |
| Share Issuances | €82.82 Million | +63.21% |
| Other Comprehensive Income | €-2.85 Million | -2.17% |
| Other Changes | €85.95 Million | +65.59% |
| Total Change | €- | 54.71% |
Book Value vs Market Value Analysis
This analysis compares Cellectis's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.08x to 2.28x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | €3.08 | €3.33 | x |
| 2008-12-31 | €3.27 | €3.33 | x |
| 2009-12-31 | €5.18 | €3.33 | x |
| 2010-12-31 | €3.55 | €3.33 | x |
| 2011-12-31 | €2.62 | €3.33 | x |
| 2012-12-31 | €3.96 | €3.33 | x |
| 2013-12-31 | €0.34 | €3.33 | x |
| 2014-12-31 | €2.82 | €3.33 | x |
| 2015-12-31 | €8.33 | €3.33 | x |
| 2016-12-31 | €7.60 | €3.33 | x |
| 2017-12-31 | €7.48 | €3.33 | x |
| 2018-12-31 | €10.04 | €3.33 | x |
| 2019-12-31 | €7.42 | €3.33 | x |
| 2020-12-31 | €6.48 | €3.33 | x |
| 2021-12-31 | €4.94 | €3.33 | x |
| 2022-12-31 | €2.59 | €3.33 | x |
| 2023-12-31 | €1.49 | €3.33 | x |
| 2024-12-31 | €1.46 | €3.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cellectis utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -88.57%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 2.93x
- Recent ROE (-28.05%) is above the historical average (-99.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -10.01% | -106.22% | 0.08x | 1.24x | €-8.71 Million |
| 2008 | 0.37% | 1.16% | 0.24x | 1.32x | €-4.45 Million |
| 2009 | -7.54% | -31.87% | 0.19x | 1.25x | €-12.84 Million |
| 2010 | -21.39% | -51.11% | 0.30x | 1.38x | €-15.74 Million |
| 2011 | -83.45% | -149.05% | 0.16x | 3.56x | €-34.60 Million |
| 2012 | -37.32% | -105.89% | 0.24x | 1.46x | €-37.34 Million |
| 2013 | -1212.90% | -369.38% | 0.52x | 6.35x | €-84.97 Million |
| 2014 | 0.03% | 0.09% | 0.16x | 2.26x | €-7.37 Million |
| 2015 | -7.81% | -40.81% | 0.15x | 1.30x | €-51.20 Million |
| 2016 | -23.48% | -150.10% | 0.13x | 1.21x | €-91.14 Million |
| 2017 | -37.25% | -394.51% | 0.08x | 1.25x | €-126.05 Million |
| 2018 | -19.23% | -618.12% | 0.03x | 1.22x | €-119.62 Million |
| 2019 | -28.78% | -597.01% | 0.03x | 1.48x | €-122.20 Million |
| 2020 | -26.33% | -98.14% | 0.16x | 1.70x | €-100.13 Million |
| 2021 | -38.99% | -116.68% | 0.19x | 1.73x | €-108.41 Million |
| 2022 | -83.66% | -514.78% | 0.07x | 2.21x | €-110.48 Million |
| 2023 | -119.32% | -13385.30% | 0.00x | 3.95x | €-109.53 Million |
| 2024 | -28.05% | -88.57% | 0.11x | 2.93x | €-49.86 Million |
Industry Comparison
This section compares Cellectis's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,186,609
- Average return on equity (ROE) among peers: -113.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cellectis (ALCLS) | €100.48 Million | -10.01% | 2.41x | $282.27 Million |
| Abionyx Pharma SA (ABNX) | $7.42 Million | -59.27% | 0.81x | $123.48 Million |
| Abivax SA (ABVX) | $11.78 Million | -260.03% | 3.39x | $6.97 Billion |
| Adocia (ADOC) | $45.85 Million | 16.61% | 0.53x | $111.73 Million |
| Aelis Farma SA (AELIS) | $1.20 Million | -263.37% | 5.00x | $18.95 Million |
| Biophytis S.A. (ALBPS) | $6.83 Million | -373.49% | 2.98x | $1.03 Million |
| Advicenne (ALDVI) | $16.92 Million | -83.89% | 0.35x | $21.67 Million |
| Genoway (ALGEN) | $1.90 Million | 0.00% | 1.85x | $30.11 Million |
| Integragen (ALINT) | $2.19 Million | 0.70% | 3.39x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.42 Million | 0.00% | 0.00x | $1.80 Million |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell p… Read more